You can add Maine to the growing list of states that have passed a law seeking more transparency about prescription drug pricing.

However, unlike a few states that quickly required drug makers to provide cost and pricing information about their medicines – California, Vermont, Nevada, and Oregon — Maine is taking a two-step approach.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • This line struck me – “passing legislation to lower drug costs should be a “top priority” for President Trump, who is expected to deliver a speech about the issue.”
    I thought the President’s objection to the last administration was ‘all talk and no action’ – the tradition continues, it would seem. (And wasn’t said speech due last week?)

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy